Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822250 | 0.85 | CYP1A2 (0.55) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL26088149 | 0.84 | CXCR4 (0.41) | CYP1A2MAPTKDM4EALDH1A1HTR1A | |
| SCHEMBL31186040 | 0.79 | CYP1A2 (0.56) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL9278258 | 0.78 | BCHE (0.49) | ALDH1A1LMNABCHEACHEMEN1 | |
| SCHEMBL14825497 | 0.77 | CYP1A2 (0.45) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL14825808 | 0.77 | CYP1A2 (0.45) | CYP1A2MAPTKDM4EALDH1A1BCHE | |
| SCHEMBL14825846 | 0.77 | OPRD1 (0.51) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL14825481 | 0.77 | CYP1A2 (0.44) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL22304487 | 0.76 | CYP1A2 (0.52) | CYP1A2MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL23790290 | 0.76 | CYP1A2 (0.44) | CYP1A2MAPTALDH1A1LMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976850-B1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20100247448-A1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-1976850-A1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007083036-A1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247448-A1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | SLC39A11, LPO, ZYX | CYP1A2 1790/4885MAPT 4780/4885KDM4E 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.